Investigational drug · Phase 3
GP681 Simulant
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Influenza, Human, Influenza.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 5, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "GP681 Simulant"
First trial start
2024
Nov 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GP681 Simulant", any sponsor or status.
Conditions studied
As listed on its trial records.
- Influenza, Human
- Influenza
Approved drugs for the same conditions: Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "GP681 Simulant" as an intervention, largest first.
- Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against InfluenzaPivotal-lookingRecruiting
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
NCT06574503 · 748 participants (planned) · Start Dec 1, 2024 · Primary completion Jul 30, 2027
Drug: GP681 40mg; GP681 Simulant · For: Influenza
Sites: Hanzhou, China
- To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus InfectionPivotal-lookingCompleted
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
NCT05474755 · 591 participants · Start Jul 28, 2022 · Primary completion Apr 25, 2023
Drug: GP681 40mg; Placebo · For: Influenza
Sites: Wenling, China
- Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza ComplicationsPivotal-lookingRecruiting
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
NCT06573008 · 328 participants (planned) · Start Nov 11, 2024 · Primary completion Dec 30, 2025
Drug: GP681 40mg; GP681 Simulant · For: Influenza, Human
Sites: Chizhou, China
- A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute InfluenzaPivotal-lookingCompleted
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
NCT04736758 · 216 participants · Start Jan 8, 2021 · Primary completion Dec 18, 2021
Drug: GP681 tablet; GP681 Simulant · For: Influenza
Sites: Nanchang, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Influenza, Human
- GP681Phase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- Flu mRNAGSK6479720A, GSK6498032APhase 22 trials
GSK · Influenza, Human
- ARCT-2304Phase 21 trial
Arcturus Therapeutics, Inc. · Influenza, Human
- DL001ZF2G22B, F2H23HPhase 21 trial
GSK · Influenza, Human
- DL001Z-NHF2H23D, F2H23BPhase 21 trial
GSK · Influenza, Human
- GSK5800544APhase 21 trial
GSK · Influenza, Human
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.